ftc report pharmacy benefit managers

Pharmacy managers inflated drug prices by $7.3 billion

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Reuters · 1d

US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.

WHAS-TV Louisville on MSN · 13h

Report: 'Pharmacy Benefit Managers' profited billions by raising prices of 'specialty drugs'

The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without substantiating evidence."

1don MSN

Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says

The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according ...

ConsumerAffairs23h

Another FTC report is highly critical of pharmacy benefit managers

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

Healthcare Dive1d

FTC releases second report slamming pharmacy benefit managers

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

KITV17h

Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds

A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results